Abstract: The present invention relates to a process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed, and recovering elongated spermatids and/or spermatozoa.

Abstract: A method for estimating a stiffness of a deformable part of a system including a four-photodiode detector for analyzing at least one characteristic of a sample. The method includes receiving the signals recorded by the four photodiodes, calculating the resultant signals from the recorded signals, calculating a cross-correlation of the resultant signals calculated for obtaining an intercorrelated signal, estimating the stiffness of the deformable part depending on the intercorrelated signal.

Abstract: The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.

Abstract: The invention relates to novel glycosidase substrates of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R?9, V, X, Y and Z are as defined in claim 1, and a method for detecting the presence of a catalytically active glycosidase by means of one of said substrates.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: The invention related to isolated peptides including a binding domain of the viral phosphoprotein (P) subunit to the viral RNA free nucleoprotein (N0) which has the property to inhibit the replication of viruses from the subfamily Paramyxovirinae (like Henipavirus, Rubulavirus or Morbillivirus). These isolated peptides may be used for the prevention or the treatment of Paramyxovirinae infection.

Abstract: The invention provides probes with formula (I): in which: X1?NH, O, or S; X2?O or S; SE is a labile group, which may be eliminated under the action of a stimulus that may in particular be the presence of an enzyme, a chemical compound, or a physicochemical characteristic of the medium in which the probe is located; A is an aromatic group that, following cleavage of the C(X2)—O bond in aqueous solution, leads to the liberation of a chromophore or a fluorophore, R represents a hydrogen atom or -(L)n-GP, in which n is equal to 0 or 1, L is a linker arm, and GP is a hydrosolubilizing group; as well as their physiologically acceptable salts, solvates, or hydrates. The invention also provides intermediates for the synthesis thereof and detection methods employing them.

Abstract: The invention relates to cationic complexes made up of a lanthanide ion Ln3+ and a ligand of formula (I) : with X, Y and R1 as defined in claim 1, and to the salts thereof with an anion, the solvates and hydrates thereof; with the exception of cationic complexes made up of a lanthanide ion Ln3+ and a ligand of one of formulae (I.1) or (I.4) as defined in claim 1, and the salts, solvates and hydrates thereof. The invention also relates to the use of such a complex or of a cationic complex made up of a lanthanide ion Ln3+ and a ligand of formula (I.1) or (I.4) as defined in claim 1, or of one of the salts thereof with an anion, the solvates or hydrates thereof, as an aid to the crystallisation of a biological macromolecule, as well as to crystallisation methods and methods for analysing or determining the structure of a biological macromolecule.

Abstract: The present invention relates to luminescent lanthanide complexes including a chelating agent, formed with a macrocycle or a set of ligands, complexing a lanthanide ion Ln3+, wherein the chelating agent is substituted with at least two groups. The invention is most particularly applied to lanthanide complexes, the chelating agent of which is formed the with three ligands integrating a 2,6 pyridine-di(carboxylic acid) or is formed with a macrocycle having a 1,4,7 triazacyclononane structure.

Abstract: Methods for diagnosing and treating CD1d-restricted gamma/delta T cell lymphomas are disclosed. In particular, the present disclosure relates to a method for diagnosing a T cell lymphoma as a CD1d-restricted gamma/delta T cell lymphoma in a patient in need thereof including i) detecting the presence of CD1d restricted gamma/delta T lymphoma cells in a cell lymphoma sample obtained from the patient and ii) concluding that the T cell lymphoma is a CD1d-restricted gamma/delta T cell lymphoma when the presence of CD1d restricted gamma/delta T cells is detected in the sample. The present disclosure also relates to a method for treating a CD1d-restricted gamma/delta T cell lymphoma as diagnosed by the diagnostic method, including administering the patient with a therapeutically effective amount of a CD1d antagonist.

Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.

Abstract: Disclosed is a method of oxidizing a cycloalkane to form a product mixture containing a corresponding alcohol and ketone, said method comprising contacting a cycloalkane with a hydroperoxide in the presence of a catalytic effective amount of a crystalline MWW-type titanosilicate catalyst. Hydroperoxides may notably be tert-butyl hydroperoxide, tert-amyl hydroperoxide, cumene hydroperoxide, ethylbenzene hydroperoxide, cyclohexyl hydroperoxide, methylcyclohexyl hydroperoxide, tetralin hydroperoxide, isobutylbenzene hydroperoxide, and ethylnaphthalene hydroperoxide.

Abstract: The invention provides probes with formula (I): in which: X1?NH, O, or S; X2?O or S; SE is a labile group, which may be eliminated under the action of a stimulus that may in particular be the presence of an enzyme, a chemical compound, or a physicochemical characteristic of the medium in which the probe is located; A is an aromatic group that, following cleavage of the C(X2)—O bond in aqueous solution, leads to the liberation of a chromophore or a fluorophore, R represents a hydrogen atom or -(L)n-GP, in which n is equal to 0 or 1, L is a linker arm, and GP is a hydrosolubilizing group; as well as their physiologically acceptable salts, solvates, or hydrates. The invention also provides intermediates for the synthesis thereof and detection methods employing them.

Abstract: The invention relates to novel peptidase substrates of formula (I): wherein R0, R1, R2, R3, R4, R5 and n are as defined in claim 1, and a method for detecting the presence of a catalytically active peptidase, by means of one of these substrates.

Abstract: The invention concerns novel glycosidase substrates of formula (I): where R0, R1, R2, R3, and R4 are such as defined in claim 1; and a method for detecting the presence of a catalytically active glycosidase using one of these substrates.

Abstract: The invention concerns a new class of tubulin polymerisation inhibitors and their applications in research and medicine, notably in chemotherapy. The invention proposes new azoaryl derivatives of formula (I): as defined in Claim 1, which may be fully reversibly interconverted between non-tubulin-binding trans and tubulin-binding as isomeric forms, either by irradiation or spontaneously.

Abstract: The present invention concerns a process to carry out an ester hydrolysis wherein the ester compound (c) is made from at least an alcohol (a) and a carboxylic acid (b), and wherein said alcohol (a) and said carboxylic acid (b) are forming a biphasic liquid system when mixed together; comprising at least a step of producing an ester compound (c)/water emulsion by using as stabilizing species amphiphilic solid particles of nanometric dimension and optionally a catalyst X.

Abstract: The present invention relates to a method of toxicological evaluation of a candidate substance on at least one tissue or organ, characterized in that it comprises the steps of: (a) obtaining a bioartificial tissue or organ by simulation or modelling of the metabolic activity of said tissue or organ by at least one bioreactor; (b) exposure of said bioartificial tissue or organ to said substance; (c) observation of the metabolic response of the bioartificial tissue or organ and acquisition without a priori of an associated multidimensional data set; (d) identification by means of a method of multivariate statistical analysis of the components of the multidimensional data set which are quantitatively correlated with predetermined variables; (e) generation of a predictive model on the basis of the components of the data set that are actually retained; (f) testing of the predictive nature of said model by at least one statistical method of estimating reliability; (g) identification of the metabolic response of the

Abstract: Non aqueous solvents or mixtures for DNP NMR spectroscopy, method to prepare said solvents or mixtures and use of said solvents or mixtures The present invention concerns a method to determine the efficiency of a solvent to impregnate a sample material for use in a dynamic nuclear polarization (DNP) nuclear magnetic resonance (NMR) experiments, characterized in that the method comprising: —selecting a non-aqueous solvent, —providing a polarizing agent that is soluble in the non-aqueous solvent, —dissolving the polarizing agent in the non-aqueous solvent, —impregnating or dissolving the sample material with the non-aqueous solvent containing the polarizing agent, —performing a solid state DNP NMR experiment on the impregnated sample material, —determining a DNP enhancement factor of the DNP NMR experiment.

Abstract: This method comprises bringing drops to be separated into contact with an interface (40) suitable for allowing an osmotic equilibrium between the content of each drop to be separated. The method comprises an osmotic flow between the drops (20A) of the first group of drops through the interface (40) in order to modify the density of each drop (20A) of the first group of drops and the separation of the drops (20A, 20B) according to the density thereof or a combination of the density and the volume in order to isolate the drops (20A) of the first group of drops from the drops (20B) of a second group of drops.